drugset / Trial / NCT01559090
Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus.
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess safety, tolerability, pharmacokinetics and pharmacodynamics of MEDI-546 in Japanese SLE patients.
Timeline
- Start
- 2012-04-20
- Primary completion
- 2014-08-19
- Completion
- 2017-02-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anifrolumab | Monoclonal antibody | 100 mg | Intravenous |
| Subject | Anifrolumab | Monoclonal antibody | 300 mg | Intravenous |
| Subject | Anifrolumab | Monoclonal antibody | 1000 mg | Intravenous |